美股市場個股詳情
NAUT Nautilus Biotechnology
- 2.730
- -0.050-1.80%
交易中 05/02 10:00 (美東)
3.42億總市值-5055市盈率TTM
2.810最高價2.730最低價1155股成交量2.810今開2.780昨收3187.80成交額0.00%換手率虧損市盈率(靜)1.25億總股本4.65052周最高1.37市淨率1.12億流通值2.27452周最低--股息TTM4113.99萬流通股25.886歷史最高--股息率TTM2.88%振幅1.500歷史最低2.760平均價1股每手
Nautilus Biotechnology股票討論區
登錄發表評論
1
$Inhibikase Therapeutics(IKT.US$
$Inhibikase Therapeutics(IKT.US$
$Inhibikase Therapeutics(IKT.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
The Company is completing 13-week pivotal toxicology studies to be submitted to the FDA for review in August.
CEO excised options
$CohBar(CWBR.US$
$CohBar(CWBR.US$
..........................................
$Fulcrum Therapeutics(FULC.US$
$Inhibikase Therapeutics(IKT.US$
$Inhibikase Therapeutics(IKT.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
The Company is completing 13-week pivotal toxicology studies to be submitted to the FDA for review in August.
CEO excised options
$CohBar(CWBR.US$
$CohBar(CWBR.US$
..........................................
$Fulcrum Therapeutics(FULC.US$
7
1
暫無評論
分析
目標價預測
暫無數據
熱議
美股
綜合熱度
股票代碼
最新價
漲跌幅
Klim5115 : 通過投資致富而富有的優勢
HunterSparks : Nextdoor 徹底改變社區生活。將在與 SPAC 公司 KVSB 合併後，並帶有代幣符號 KIND。非常適合其應用的股票符號。在上市前可以通過 KVSB 獲得曝光